Quoin Pharma wins FDA fast track status for QRX003 in peeling skin syndrome
Bitget2026/09/22 12:33- FDA granted Fast Track designation to Quoin’s QRX003 for Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment.
- Marks the first Fast Track designation for any Peeling Skin Syndrome therapy; QRX003 previously received Fast Track for Netherton Syndrome in March 2026.
- Quoin plans to start a Phase 2/3 trial in 2H 2026; it is targeting approval in 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Crypto prices
More
